Moleculin Biotech, Inc. (MBRX)
NASDAQ
Real-time Data
01:30 PM
Day's Range
0.413052 wk Range
0.1610Overview - MBRX - Moleculin Biotech, Inc.
Key Statistics
Valuation
Enterprise Value
1.63M
P/E (Trailing)
‪0.04‬
P/E (Forward)
‪-0.0040‬
PEG Ratio
‪-0.00055‬
Price / Book
‪0.27‬
EV / EBITDA
‪-0.05‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-84.56%‬
Return on Equity
‪-1,371.64%‬
Ownership
Shares Outstanding
7.10M
Float
17.03M
Short % of Shares Outstanding
‪1.01%‬
Held by Insiders
‪6.12%‬
Held by Institutions
‪8.18%‬
Price stats
Beta
‪2.00‬
50-Day Avg
‪0.5796‬
200-Day Avg
‪2.28‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
3 analysts
Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - MBRX - Moleculin Biotech, Inc.
Peers - MBRX - Moleculin Biotech, Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- MBRXNASDAQMoleculin Biotech, Inc.9.01MMarket Cap-2547.06%52-week change0.05P/E (Trailing)‪0.00%‬Profit Margin
- ARGXNASDAQArgenx SE51.88BMarket Cap+3.09%52-week change31.44P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals, Inc.31.13BMarket Cap-99.82%52-week change39.24P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE American Depositary Share24.35BMarket Cap-5.51%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S15.08BMarket Cap+9.07%52-week change17.06P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma Inc.12.77BMarket Cap+14.37%52-week change-17.29P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBioMarin Pharmaceutical Inc.11.06BMarket Cap+2.75%52-week change154.54P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - MBRX - Moleculin Biotech, Inc.
About
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for hard-to-treat cancers and viral infections. Its current pipeline centers on Annamycin, an anthracycline-based candidate being evaluated in combination regimens for relapsed or refractory acute myeloid leukemia and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
